Olmetec is indicated for the treatment of essential hypertension.
Renal impairment: Dosage of olmesartan medoxomil should be individualized in patients with renal impairment.
The maximum dose in patients with mild to moderate renal impairment (creatinine clearance of 20 – 60 mL/min) is 20 mg olmesartan medoxomil once daily, owing to limited experience of higher dosages in this patient group.
Hepatic impairment: No adjustment of dosage recommendations is required for patients with mild hepatic impairment. In patients with moderate hepatic impairment, an initial dose of 10 mg olmesartan medoxomil once daily is recommended and the maximum dose should not exceed 20 mg once daily. Close monitoring of blood pressure and renal function is advised in hepatically-impaired patients who are already receiving diuretics and/or other antihypertensive agents.
Paediatric population: The safety and efficacy of olmesartan medoxomil in children and adolescents below 18 years has not been established.